For citations:
Pomytkin I.A., Pisarev V.V., Merkulov M.E., Kuznetsova E.B., Salina E.A., Malygin A.Yu., Karkischenko N.N. Phase II Clinical Trial of Direkord: Randomized, Double-Blind, Placebo-Controlled, Parallel Group, and Prospective Studies to Select Optimal Dosage and to Study the Efficacy, Safety, and Tolerability in Ischemic Stroke Patients in the Early Recovery Period. Journal Biomed. 2023;19(3):87-96. (In Russ.) https://doi.org/10.33647/2074-5982-19-3-87-96
Email this article 
